S&P 500   4,599.54 (+0.71%)
DOW   34,623.65 (+0.41%)
QQQ   396.63 (+0.71%)
AAPL   169.42 (+2.49%)
MSFT   336.97 (+1.93%)
FB   317.51 (-2.14%)
GOOGL   2,884.28 (+1.63%)
AMZN   3,510.51 (+0.10%)
TSLA   1,143.80 (-0.08%)
NVDA   325.42 (-0.41%)
BABA   124.70 (-2.22%)
NIO   39.67 (+1.38%)
CGC   10.36 (-3.27%)
AMD   155.05 (-2.10%)
GE   95.69 (+0.74%)
MU   87.90 (+4.64%)
T   22.58 (-1.10%)
F   20.05 (+4.48%)
DIS   145.26 (+0.25%)
PFE   54.46 (+1.36%)
ACB   6.26 (-2.49%)
AMC   32.66 (-3.77%)
BA   194.63 (-1.63%)
S&P 500   4,599.54 (+0.71%)
DOW   34,623.65 (+0.41%)
QQQ   396.63 (+0.71%)
AAPL   169.42 (+2.49%)
MSFT   336.97 (+1.93%)
FB   317.51 (-2.14%)
GOOGL   2,884.28 (+1.63%)
AMZN   3,510.51 (+0.10%)
TSLA   1,143.80 (-0.08%)
NVDA   325.42 (-0.41%)
BABA   124.70 (-2.22%)
NIO   39.67 (+1.38%)
CGC   10.36 (-3.27%)
AMD   155.05 (-2.10%)
GE   95.69 (+0.74%)
MU   87.90 (+4.64%)
T   22.58 (-1.10%)
F   20.05 (+4.48%)
DIS   145.26 (+0.25%)
PFE   54.46 (+1.36%)
ACB   6.26 (-2.49%)
AMC   32.66 (-3.77%)
BA   194.63 (-1.63%)
S&P 500   4,599.54 (+0.71%)
DOW   34,623.65 (+0.41%)
QQQ   396.63 (+0.71%)
AAPL   169.42 (+2.49%)
MSFT   336.97 (+1.93%)
FB   317.51 (-2.14%)
GOOGL   2,884.28 (+1.63%)
AMZN   3,510.51 (+0.10%)
TSLA   1,143.80 (-0.08%)
NVDA   325.42 (-0.41%)
BABA   124.70 (-2.22%)
NIO   39.67 (+1.38%)
CGC   10.36 (-3.27%)
AMD   155.05 (-2.10%)
GE   95.69 (+0.74%)
MU   87.90 (+4.64%)
T   22.58 (-1.10%)
F   20.05 (+4.48%)
DIS   145.26 (+0.25%)
PFE   54.46 (+1.36%)
ACB   6.26 (-2.49%)
AMC   32.66 (-3.77%)
BA   194.63 (-1.63%)
S&P 500   4,599.54 (+0.71%)
DOW   34,623.65 (+0.41%)
QQQ   396.63 (+0.71%)
AAPL   169.42 (+2.49%)
MSFT   336.97 (+1.93%)
FB   317.51 (-2.14%)
GOOGL   2,884.28 (+1.63%)
AMZN   3,510.51 (+0.10%)
TSLA   1,143.80 (-0.08%)
NVDA   325.42 (-0.41%)
BABA   124.70 (-2.22%)
NIO   39.67 (+1.38%)
CGC   10.36 (-3.27%)
AMD   155.05 (-2.10%)
GE   95.69 (+0.74%)
MU   87.90 (+4.64%)
T   22.58 (-1.10%)
F   20.05 (+4.48%)
DIS   145.26 (+0.25%)
PFE   54.46 (+1.36%)
ACB   6.26 (-2.49%)
AMC   32.66 (-3.77%)
BA   194.63 (-1.63%)
NASDAQ:IMNM

Immunome Stock Forecast, Price & News

$16.62
-2.33 (-12.30%)
(As of 12/1/2021 12:57 PM ET)
Add
Compare
Today's Range
$16.62
$27.00
50-Day Range
$14.57
$27.76
52-Week Range
$9.27
$63.78
Volume
5,614 shs
Average Volume
260,403 shs
Market Capitalization
$201.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive IMNM News and Ratings via Email

Sign-up to receive the latest news and ratings for Immunome and its competitors with MarketBeat's FREE daily newsletter.


Immunome logo

About Immunome

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.

Headlines

Immunome to Present at the Stifel Healthcare Conference
November 10, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IMNM
Fax
N/A
Employees
2,020
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$3.92 per share

Profitability

Net Income
$-17.84 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
9,777,000
Market Cap
$201.10 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/15/2021
Today
12/01/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/24/2022

MarketRank

Overall MarketRank

2.16 out of 5 stars

Medical Sector

417th out of 1,392 stocks

Pharmaceutical Preparations Industry

190th out of 669 stocks

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -












Immunome (NASDAQ:IMNM) Frequently Asked Questions

Is Immunome a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immunome in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Immunome stock.
View analyst ratings for Immunome
or view top-rated stocks.

Are investors shorting Immunome?

Immunome saw a decrease in short interest in the month of October. As of October 15th, there was short interest totaling 212,300 shares, a decrease of 18.3% from the September 30th total of 259,900 shares. Based on an average daily trading volume, of 149,500 shares, the short-interest ratio is presently 1.4 days. Currently, 2.5% of the company's stock are short sold.
View Immunome's Short Interest
.

When is Immunome's next earnings date?

Immunome is scheduled to release its next quarterly earnings announcement on Thursday, March 24th 2022.
View our earnings forecast for Immunome
.

How were Immunome's earnings last quarter?

Immunome, Inc. (NASDAQ:IMNM) announced its quarterly earnings results on Monday, November, 15th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.51) by $0.14.
View Immunome's earnings history
.

What price target have analysts set for IMNM?

2 Wall Street analysts have issued 12 month price objectives for Immunome's stock. Their forecasts range from $21.00 to $35.00. On average, they anticipate Immunome's share price to reach $28.00 in the next twelve months. This suggests a possible upside of 68.5% from the stock's current price.
View analysts' price targets for Immunome
or view top-rated stocks among Wall Street analysts.

Who are Immunome's key executives?

Immunome's management team includes the following people:
  • Dr. Purnanand Duddu Sarma, Pres, CEO & Director (Age 56, Pay $657.44k)
  • Dr. Michael J. Morin, Chief Scientific Officer (Age 66, Pay $377.11k)
  • Ms. Sandra G. Stoneman Esq., Chief Legal Officer, Gen. Counsel & Corp. Sec. (Age 48, Pay $443.43k)
  • Ms. Corleen M. Roche, Chief Financial Officer
  • Mr. Matthew K. Robinson Ph.D., Sr. VP of R&D
  • Dr. Dennis H. Giesing, Chief Devel. Officer (Age 69)

When did Immunome IPO?

(IMNM) raised $30 million in an initial public offering on Friday, October 2nd 2020. The company issued 2,500,000 shares at $11.00-$13.00 per share. Ladenburg Thalmann and Chardan acted as the underwriters for the IPO.

What is Immunome's stock symbol?

Immunome trades on the NASDAQ under the ticker symbol "IMNM."

Who are Immunome's major shareholders?

Immunome's stock is owned by many different institutional and retail investors. Top institutional investors include Cerity Partners LLC (0.84%), Geode Capital Management LLC (0.45%), BlackRock Inc. (0.34%), Ridgewood Investments LLC (0.23%), Millennium Management LLC (0.17%) and Citadel Advisors LLC (0.00%). Company insiders that own Immunome stock include Michael Lefenfeld, Michael Rapp and Purnanand D Sarma.
View institutional ownership trends for Immunome
.

Which institutional investors are selling Immunome stock?

IMNM stock was sold by a variety of institutional investors in the last quarter, including Ridgewood Investments LLC, Millennium Management LLC, and Cerity Partners LLC.
View insider buying and selling activity for Immunome
or view top insider-selling stocks.

Which institutional investors are buying Immunome stock?

IMNM stock was purchased by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, HAP Trading LLC, BlackRock Inc., Geode Capital Management LLC, Baldwin Investment Management LLC, Marshall Wace LLP, and Morgan Stanley. Company insiders that have bought Immunome stock in the last two years include Michael Lefenfeld, Michael Rapp, and Purnanand D Sarma.
View insider buying and selling activity for Immunome
or or view top insider-buying stocks.

How do I buy shares of Immunome?

Shares of IMNM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Immunome's stock price today?

One share of IMNM stock can currently be purchased for approximately $16.62.

How much money does Immunome make?

Immunome has a market capitalization of $201.10 million. The company earns $-17.84 million in net income (profit) each year or ($1.88) on an earnings per share basis.

How many employees does Immunome have?

Immunome employs 2,020 workers across the globe.

What is Immunome's official website?

The official website for Immunome is immunome.com.

How can I contact Immunome?

The company can be reached via phone at 610-321-3700 or via email at [email protected].


This page was last updated on 12/1/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.